^
Association details:
| Biomarker: | RBBP8 E281 |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A novel RBBP8(p.E281*) germline mutation is a predisposing mutation in familial hereditary cancer syndrome
Published date:
08/24/2023
Excerpt:
...we examined the effects of PARP inhibitors (olaparib) and platinum (cisplatin) on the proliferation of breast cancer cells harboring the novel RBBP8 germline mutation (p.E281*). The CCK8 assay revealed that compared with the control group, the RBBP8(p.E281*) group showed elevated cell death in response to cisplatin and olaparib treatment...Patients with RBBP8(p.E281*) germline mutation may benefit from Olaparib, Cisplatin
DOI:
10.1007/s00109-023-02354-z
